Millennium Management LLC Has $223,000 Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Millennium Management LLC trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 90.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,634 shares of the company's stock after selling 265,889 shares during the quarter. Millennium Management LLC's holdings in ORIC Pharmaceuticals were worth $223,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in shares of ORIC Pharmaceuticals in the fourth quarter worth about $50,000. BNP Paribas Financial Markets bought a new position in shares of ORIC Pharmaceuticals during the 4th quarter worth about $71,000. PNC Financial Services Group Inc. boosted its holdings in ORIC Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after purchasing an additional 2,520 shares in the last quarter. Janus Henderson Group PLC bought a new stake in ORIC Pharmaceuticals in the fourth quarter valued at $118,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of ORIC Pharmaceuticals by 1,048.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,661 shares of the company's stock worth $118,000 after purchasing an additional 13,384 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

Insiders Place Their Bets

In other ORIC Pharmaceuticals news, CFO Dominic Piscitelli sold 2,976 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $10.01, for a total value of $29,789.76. Following the transaction, the chief financial officer now directly owns 102,117 shares of the company's stock, valued at $1,022,191.17. This represents a 2.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 6,200 shares of company stock valued at $62,056 over the last ninety days. 6.82% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ORIC has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. Cantor Fitzgerald restated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, May 6th. Oppenheimer decreased their price target on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, ORIC Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $19.17.

ORIC Pharmaceuticals Trading Up 3.0%

Shares of NASDAQ:ORIC traded up $0.28 during trading on Thursday, hitting $9.67. 814,754 shares of the company were exchanged, compared to its average volume of 773,618. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock has a market cap of $687.42 million, a price-to-earnings ratio of -5.31 and a beta of 1.49. The firm has a fifty day moving average price of $6.04 and a two-hundred day moving average price of $7.71.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. As a group, research analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.